Order results by:
Issue | Title | |
Vol 5, No 5 (2009) | EFFECTS OF ACETYLSALICYLIC ACID AND CLOPIDOGREL ON MORPHOFUNCTIONAL STATUS OF ERYTHROCYTES IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
A. L. Alyavi, R. A. Rakhimov, B. A. Alyavi | ||
"... and morphology of erythrocytes and to assess their changes during therapy with acetylsalicylic acid, emclopidogrel/em ..." | ||
Vol 8, No 2 (2012) | RESIDUAL PLATELET REACTIVITY DURING THERAPY WITH INHIBITORS OF CYCLOOXIGENASE OR ADENOSINE DIPHOSPHATE RECEPTORS | Abstract similar documents |
A. A. Lomonosova, N. A. Mazur, E. A. Zolozova, E. V. Sayutina, V. V. Chigineva, N. V. Shestakova | ||
"... Aim. To compare effects of emacetylsalicylic/em acid (ASA) and two emclopidogrel/em drugs on residual ..." | ||
Vol 12, No 4 (2016) | High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice | Abstract similar documents |
N. F. Puchinyan, N. V. Furman, P. V. Dolotovskaya, L. L. Malinova | ||
"... antiplatelet therapy (DAT) with emacetylsalicylic/em acid (ASA) and emclopidogrel/em by optical aggregometry in patients ..." | ||
Vol 4, No 2 (2008) | ANTIPLATELET THERAPY RESISTANCE IN PATIENTS WITH ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION | Abstract similar documents |
D. H. Ainetdinova, A. Е. Udovichenko, V. A. Sulimov | ||
"... Aim. To evaluate the incidence of emacetylsalicylic/em acid (ASA) and emclopidogrel/em resistance ..." | ||
Vol 3, No 3 (2007) | RESISTANCE TO ANTIPLATELET DRUGS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
D. H. Aynetdinova, A. E. Udovichenko, V. A. Sulimov | ||
Vol 7, No 6 (2011) | ANTI-INFLAMMATORY EFFECT OF CLOPIDOGREL IN ATHEROSCLEROSIS | Abstract similar documents |
L. I. Buriachkovskaia, A. B. Sumarokov, I. A. Uchitel, E. M. Gupalo | ||
"... Aim. To analyze the literary and own data about emclopidogrel/em influence on platelets during ..." | ||
Vol 13, No 5 (2017) | INFLUENCE OF SWITCHING OF CLOPIDOGREL TO TICAGRELOR ON THE DEVELOPMENT OF CARDIOVASCULAR EVENTS IN PATIENTS WITH ST SEGMENT ELEVATION | Abstract similar documents |
E. V. Tavlueva, A. V. Alekseenko, O. V. Gruzdeva, O. L. Barbarash | ||
"... doses of emacetylsalicylic/em acid (250 mg) and emclopidogrel/em (600 mg). After 12-24 hours, the patients were ..." | ||
Vol 5, No 3 (2009) | ANTIPLATELET DRUGS RESISTANCE IN PATIENTS WITH ISCHEMIC HEART DISEASE AND OBLITERATIVE ATHEROSCLEROSIS OF LOWER LIMB ARTERIES ASSOCIATED WITH DIABETES MELLITUS TYPE 2 | Abstract similar documents |
E. V. Gorjacheva, A. E. Udovichenko, V. A. Sulimov, N. V. Lavrishcheva, M. A. Surikova, T. N. Gracheva | ||
"... Aim. To study a rate of resistance to emacetylsalicylic/em acid (ASA) and emclopidogrel/em and clinical ..." | ||
Vol 6, No 4 (2010) | CLOPIDOGREL PHARMACOGENETICS | Abstract similar documents |
A. N. Meshkov | ||
"... agents all over the world is emclopidogrel/em, R2Y12-receptor blocker. It is shown that emclopidogrel/em has ..." | ||
Vol 9, No 1 (2013) | POSSIBILITIES OF CLINICAL LABORATORY EVALUATION OF ANTIPLATELET THERAPY EFFECTIVENESS IN PATIENTS WITH ISCHEMIC HEART DISEASE | Abstract similar documents |
O. V. Sirotkina, A. B. Laskovets, A. S. Lipunova, L. B. Gaykovaya, S. A. Boldueva, T. V. Vavilova | ||
"... and induced flow cytofluorometry during antiplatelet therapy with emclopidogrel/em and emacetylsalicylic/em acid (ASA ..." | ||
Vol 8, No 1 (2012) | RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION | Abstract similar documents |
V. A. Sulimov, E. V. Moroz | ||
"... Aim. To study prevalence of resistance to emacetylsalicylic/em acid, emclopidogrel/em and dual resistance ..." | ||
Vol 12, No 5 (2016) | Features of the Hemostasis and Platelets Enzyme Activity in Patients with Different Sensitivity to Acetylsalicylic Acid by the Acute Coronary Syndrome | Abstract similar documents |
I. Yu. Grinshtein, A. A. Savchenko, Yu. I. Grinshtein, M. M. Petrova | ||
"... in emacetylsalicylic/em acid (ASA) sensitive and resistant patients with acute coronary syndrome (ACS). Material ..." | ||
Vol 6, No 2 (2010) | THE MODERN ASPECTS OF CLOPIDOGREL USE | Abstract similar documents |
E. N. Dankovtseva, D. A. Zateyshchikov | ||
"... The possibilities and evidence base of emclopidogrel/em use in clinical practice are discussed. Data ..." | ||
Vol 2, No 3 (2006) | ANTITHROMBOTIC THERAPY OF ISCHEMIC HEART DISEASE: FROM FAST ACTING ANTIAGGREGANTS TO STATINES AND NITRATE OXIDE. IS IT REAL? | Abstract similar documents |
I. A. Latfullin, A. A. Podolskaya | ||
"... of action and clinical efficiency of antithrombotic and antiplatelet medicines such as emacetylsalicylic/em acid ..." | ||
Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
"... 1565C), ITGA2 (C807T), eNOS3 (T786C) genes with high residual platelet reactivity (HRPR) to emclopidogrel/em ..." | ||
Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
"... 140 patients in the emacetylsalicylic/em acid (ASA) treatment group and 103 patients in the dual ..." | ||
Vol 8, No 2 (2012) | UP TO DATE ANTIPLATELET THERAPY IN PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS AND REAL CLINICAL PRACTICE | Abstract similar documents |
S. Yu. Martsevich, V. P. Voronina, M. L. Ginzburg, N. P. Kutishenko, Yu. N. Polyanskaya, T. G. Kheliya, A. M. Malysheva, S. N. Tolpygina, V. S. Kutuzova, E. A. Gofman, A. D. Deev | ||
"... Aim. To assess the real rate of dual antiplatelet therapy (DAT, emacetylsalicylic/em acid + emclopidogrel/em ..." | ||
Vol 15, No 3 (2019) | Study of the Association of V640L (rs6133) Polymorphism in the Platelet P-selectin Gene with Acetylsalicylic Acid Resistance in Patients after Coronary Bypass Surgery | Abstract similar documents |
A. A. Kosinova, T. S. Mongush, M. D. Goncharov, T. N. Subbotina, K. S. Semashchenko, G. Y. Kochmareva, Yu. I. Grinshtein | ||
"... with emacetylsalicylic/em acid (ASA) resistance in patients with coronary heart disease after coronary bypass surgery (CABG ..." | ||
Vol 11, No 1 (2015) | EVALUATION OF PLATELET AGGREGATION IN CLINICAL PRACTICE | Abstract similar documents |
K. B. Mirzaev, D. A. Andreev, D. A. Sychev | ||
"... of emclopidogrel/em, the association of residual platelet reactivity with clinical outcomes and a review ..." | ||
Vol 7, No 1 (2011) | THE ROLE OF MODERN ANTIPLATELET THERAPY IN PREVENTION OF ATHEROTHROMBOSIS: THE IMPORTANCE OF CLOPIDOGREL AND ITS GENERIC DRUGS | Abstract similar documents |
O. V. Gaisenok | ||
"... in patients with cardioascular diseases are discussed. Role of emclopidogrel/em in contemporary antiplatelet ..." | ||
Vol 7, No 4 (2011) | ON THE 125TH ANNIVERSARY OF ACETYLSALICYLIC ACID | Abstract similar documents |
I. N. Bokarev, L. V. Popova | ||
"... An experience of emacetylsalicylic/em acid (ASA) clinical use since its synthesis in 1887 ..." | ||
Vol 7, No 1 (2011) | THERAPEUTIC EQUIVALENCE OF ORIGINAL CLOPIDOGREL (PLAVIX) AND ITS GENERIC (EGITROMB). RESULTS OF COMPARATIVE RANDOMIZED CROSS-OVER BLIND STUDY | Abstract similar documents |
V. V. Yakusevich, A. S. Petrochenko, V. A. Simonov, N. Yu. Levshin, A. D. Deev | ||
"... Aim. To study therapeutic equivalence (efficacy, safety and tolerability) of original emclopidogrel/em ..." | ||
Vol 10, No 6 (2014) | СONCOMITANT ADMINISTRATION OF CLOPIDOGREL AND PROTON PUMP INHIBITORS: ARE THERE ANY OPEN QUESTIONS LEFT TODAY? | Abstract similar documents |
S. Yu. Martsevich, A. Yu. Suvorov | ||
"... Concomitant administration of emclopidogrel/em and proton pump inhibitors (PPI), the possible influence ..." | ||
Vol 12, No 3 (2016) | CLINICAL AND LABORATORY CHARACTERISTICS OF PATIENTS WITH ISCHEMIC HEART DISEASE RESISTANT TO ACETYLSALICYLIC ACID IN PERIOPERATIVE PERIOD OF CORONARY ARTERY BYPASS GRAFT: RESULTS OF AN OPEN PROSPECTIVE STUDY | Abstract PDF (Eng) similar documents |
Yu. I. Grinshtein, A. A. Kosinova, I. Yu. Grinshtein, A. V. Kovalev, V. G. Sukhovol'skiy, A. A. Savchenko | ||
"... that are sensitive or resistant to emacetylsalicylic/em acid (ASA) before and after coronary artery bypass graft (CABG ..." | ||
Vol 9, No 4 (2013) | ACETYLSALICYLIC ACID: CONTROVERSIAL AND OUTSTANDING ISSUES | Abstract similar documents |
E. N. Dankovtseva | ||
"... Review of current ideas about the role of emacetylsalicylic/em acid (ASA) in the primary prevention ..." | ||
Vol 8, No 2 (2012) | ACETYLSALICYLIC ACID IN THE PREVENTION OF ATHEROTHROMBOTIC EVENTS | Abstract similar documents |
A. V. Govorin, A. P. Filev | ||
"... of emacetylsalicylic/em acid (ASA) in primary and secondary prevention of atherothrombotic events. Studies on the safety ..." | ||
Vol 9, No 4 (2013) | THE SIGNIFICANCE OF PHARMACOGENETIC CYP2C19 TESTING FOR PERSONALIZATION OF THE ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
K. B. Mirzaev, D. A. Sychev, D. A. Andreev, A. B. Prokofiev | ||
"... of the formation of the active emclopidogrel/em metabolite, for efficacy and safety of this drug in cardiology practice ..." | ||
Vol 6, No 4 (2010) | ACC/AHA CLOPIDOGREL CLINICAL ALERT. WHAT MUST BE MODERN ANTIPLATELET THERAPY? | Abstract similar documents |
S. J. Martsevich | ||
"... The ACC/AHA emclopidogrel/em clinical alert about the possibility of ineffective treatment ..." | ||
Vol 13, No 1 (2017) | ANTIPLATELET THERAPY OF ATRIAL FIBRILLATION: FOCUS ON THE ELDERLY | Abstract similar documents |
E. А. Ushkalova, S. K. Zyryanov, E. V. Dumchenko | ||
"... that risk associated with emacetylsalicylic/em acid (ASA) use in patients ≥75 years can overweigh its potential ..." | ||
Vol 8, No 4 (2012) | ACETYLSALICYLIC ACID: WHAT'S NEW IN THE OLD DRUG? | Abstract similar documents |
I. V. Zhirov | ||
"... The results of recent trials on emacetylsalicylic/em acid (ASA) efficacy are presented. Data ..." | ||
Vol 14, No 2 (2018) | WHAT ARE THE OPPORTUNITIES OF PRASUGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
M. Yu. Gilyarov, Е. V. Konstantinova | ||
"... atherosclerotic plaque. The use of emacetylsalicylic/em acid with addition of the second antiplatelet agent, so-called ..." | ||
Vol 8, No 5 (2012) | ACETYLSALICYLIC ACID: DO WE KNOW EVERYTHING ABOUT IT AND ITS PROPER USE? | Abstract similar documents |
S. A. Boldueva, I. A. Leonova | ||
"... Use of emacetylsalicylic/em acid (ASA) in cardiology practice is presented. ASA modes of action ..." | ||
Vol 5, No 6 (2009) | ACETYLSALICYLIC ACID IN LOW DOSES FOR SECONDARY PREVENTION OF CARDIO-VASCULAR COMPLICATIONS | Abstract similar documents |
N. A. Dmitrieva, S. N. Tolpygina | ||
"... Data of evidence based medicine which confirm efficacy of emacetylsalicylic/em acid (ACA ..." | ||
Vol 13, No 1 (2017) | MONITORING OF THE EFFECTIVENESS OF ANTIPLATELET THERAPY IN CARDIOLOGY PRACTICE | Abstract similar documents |
N. F. Puchinian, N. V. Furman, L. I. Malinova, P. V. Dolotovskaya | ||
Vol 7, No 3 (2011) | MODERN ANTIPLATELET THERAPY OF ISCHEMIC HEART DISEASE PATIENTS WITH HIGH RISK OF THROMBOTIC EVENTS: DATA FROM EVIDENCE-BASED MEDICINE AND REAL PRACTICE | Abstract similar documents |
S. Yu. Martsevich, M. L. Ginzburg, A. M. Malysheva, Yu. N. Polyanskaya, T. G. Kheliya, N. P. Kutishenko | ||
"... Aim. To study a rate of emclopidogrel/em use in patients having indications for emclopidogrel/em therapy ..." | ||
Vol 8, No 2 (2012) | EFFICACY AND SAFETY OF ACETYLSALICYLIC ACID IN PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES | Abstract similar documents |
S. N. Tolpygina, S. Yu. Martsevich, E. N. Khoseva, N. V. Kiseleva | ||
"... emAcetylsalicylic/em acid (ASA) use in the primary and secondary prevention of cardiovascular diseases ..." | ||
Vol 20, No 6 (2024) | Platelet reactivity clinical and biochemical markers when taking acetylsalicylic acid as part of dual antiplatelet therapy in the myocardial infarction subacute period | Abstract similar documents |
T. P. Pronko, V. A. Snezhitskiy, A. V. Kapytski | ||
"... of myocardial infarction (MI) during the administration of emacetylsalicylic/em acid (ASA) as part of dual ..." | ||
Vol 10, No 5 (2014) | DUAL ANTIPLATELET THERAPY IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
G. N. Guseva, T. V. Pavlova, I. L. Voronova, S. M. Chohlunov | ||
"... .8% of patients also received combination of emclopidogrel/em and emacetylsalicylic/em acid, but changed medicinal products ..." | ||
Vol 14, No 1 (2018) | NFLUENCE OF CYP4F2*3 ON RESPONSE TO CLOPIDOGREL IN PATIENTS WITH ACUTE CORONARY SYNDROME | Abstract similar documents |
K. B. Mirzaev, O. D. Konova, E. A. Grishina, K. A. Ryzhikova, Zh. A. Sozaeva, D. A. Andreev, M. Y. Gilyarov, D. A. Sychev | ||
"... effect of emclopidogrel/em, thus changing efficacy and safety of its standard dose. Aim. To study the impact ..." | ||
Vol 14, No 5 (2018) | Pharmacogenetic and Clinical Predictors of Clopidogrel Insufficiency in a Patient with Atherosclerosis Obliterans of the Lower Extremities: Clinical Case | Abstract similar documents |
M. A. Andreyanova, K. B. Mirzaev, D. A. Sychev, K. A. Ryzhikova, A. V. Pokrovsky, A. F. Kharazov | ||
"... for resistance to antiplatelet therapy with emclopidogrel/em. The decrease in the effectiveness of prolonged therapy ..." | ||
Vol 5, No 4 (2009) | GASTROENTEROPATHIES ASSOCIATED WITH ACETYLSALICYLIC ACID: HOW TO IMPROVE SAFETY OF THERAPY | Abstract similar documents |
A. L. Komarov | ||
"... Lesion of gastrointestinal mucous coat is the main factor limited emacetylsalicylic/em acid (ASA) use ..." | ||
Vol 3, No 4 (2007) | RESISTANCE TO ACETYLSALICYLIC ACID AND PREVALENCE OF THROMBOSIS IN PATIENTS WITH STABLE ANGINA | Abstract similar documents |
N. F. Putchinyan, N. V. Furman, P. Ya. Dovgalevskyi | ||
"... sensitivity to emacetylsalicylic/em acids (ASA) in patients with stable angina. Material and methods. 96 patients ..." | ||
Vol 14, No 3 (2018) | APPROACHES TO THE CHOICE OF ANTICOAGULANT THERAPY IN THE TREATMENT OF PATIENTS WITH COMBINATION OF ATRIAL FIBRILLATION WITH CORONARY HEART DISEASE OR PERIPHERAL ATHEROSCLEROSIS: POTENTIAL OF APIXABAN | Abstract similar documents |
O. D. Ostroumova, A. I. Kochetkov, I. Yu. Orlova, E. A. Smolyarchuk, J. S. Pavlova | ||
"... in trials and proven efficacy in the prevention of stroke/systemic embolism, the use of emclopidogrel/em ..." | ||
Vol 13, No 6 (2017) | CYP2C19 PHARMACOGENETIC TESTING FOR PERSONALIZATION OF ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME IN ROUTINE CLINICAL PRACTICE | Abstract similar documents |
A. I. Akhmetova, E. B. Kleimenova, D. A. Sychev, O. V. Parshina, L. P. Yashina | ||
"... .5%) patients received emclopidogrel/em, 17 (16.5%) – ticagrelor. After therapy correction based on genotype GA ..." | ||
Vol 16, No 6 (2020) | Modern Antiplatelet Therapy for Percutaneous Coronary Intervention. How to Make the Right Choice? | Abstract similar documents |
T. M. Uskach, A. S. Tereshchenko | ||
"... pronounced platelet inhibition than emclopidogrel/em. The drugs differ in pharmacodynamics and platelet reactivity ..." | ||
Vol 7, No 5 (2011) | HIGH VERSUS STANDARD CLOPIDOGREL MAINTENANCE DOSE AFTER PERCUTANEOUS CORONARY INTERVENTION AND EFFECTS ON PLATELET INHIBITION, ENDOTHELIAL FUNCTION, AND INFLAMMATION. RESULTS OF THE ARMYDA-150 MG (ANTIPLATELET THERAPY FOR REDUCTION OF MYOCARDIAL DAMAGE DURING ANGIOPLASTY) RANDOMIZED STUDY | similar documents |
G. Patti, D. Grieco, G. Dicuonzo, V. Pasceri, A. Nusca, G. Sciascio | ||
"... Введение. Полученные ранее данные свидетельствуют о наличии у emклопидогрела/em не только ..." | ||
Vol 4, No 1 (2008) | COMPARISON OF ANTIPLATELET EFFECT AND SAFETY OF ORIGINAL DRUG «ASPIRIN CARDIO» AND GENERIC«ACECARDOL» IN PATIENTS WITH ARTERIAL HYPERTENSION 1-2 GRADE | Abstract similar documents |
N. A. Belolipetskiy, S. N. Tolpygina, O. А. Litinskaya, V. G. Belolipetskaya, S. Yu. Martsevich | ||
"... Aim. To compare antiplatelet effect of two emacetylsalicylic/em acid medicines, Acecardol ("Synthesis ..." | ||
Vol 5, No 6 (2009) | RISK OF REPEATED THROMBOTIC EVENTS IN PATIENTS SURVIVED ACUTE CORONARY SYNDROME AND HAVING LABORATORY PROVEN RESISTANCE TO ACETYLSALICYLIC ACID | Abstract similar documents |
N. F. Puchinyan, N. V. Furman, A. R. Kiselev, Ya. P. Dovgalevsky | ||
"... to emacetylsalicylic/em acid (ASA) therapy. Material and methods. 200 patients with ACS (aged 56,6±9,2 y.o.) were ..." | ||
Vol 6, No 6 (2010) | COMPARISON OF ANTIPLATELET EFFICACY OF ORIGINAL AND GENERIC ENTEROSOLUBLE ACETYLSALICYLIC ACID IN PATIENTS WITH HIGH CARDIOVASCULAR RISK. SIMPLE BLIND CROSSED RANDOMIZED CONTROLLED STUDY (IKAR) | Abstract similar documents |
S. Yu. Martsevich, S. N. Tolpygina, E. S. Boychenko, R. E. Dubinskaya, Yu. V. Lukina, V. P. Voronina | ||
"... emacetylsalicylic/em acid (ASA) in patients with high cardiovascular risk. Material and мethods. Patients (n=30 ..." | ||
Vol 11, No 4 (2015) | INFLUENCE OF THE CYP3A4 ISOENZYME METABOLIC ACTIVITY AND CYP2C19 GENE POLYMORPHISMS ON CLOPIDOGREL ANTIPLATELET EFFECT IN PATIENTS WITH ACUTE CORONARY SYNDROME UNDERGOING PERCUTANEOUS CORONARY INTERVENTION | Abstract PDF (Eng) similar documents |
K. B. Mirzaev, R. E. Kazakov, V. V. Smirnov, D. A. Andreev, D. A. Sychev | ||
"... of emclopidogrel’s/em active metabolite and, respectively, its antiplatelet effect. We sought to determine the impact ..." | ||
Vol 14, No 6 (2018) | P2Y12 Receptor Inhibitors in the Treatment of Patients with Acute Coronary Syndrome and Percutaneous Coronary Intervention: Possibilities of Prasugrel | Abstract PDF (Eng) similar documents |
N. M. Vorobyeva | ||
"... with emclopidogrel/em or ticagrelor was performed, as well as of all 3 P2Y12-receptor inhibitors among themselves ..." | ||
Vol 17, No 1 (2021) | Aspirin Resistance as a Result of Impaired Interaction of Platelets and Neutrophils in Patients with Coronary Heart Disease | Abstract similar documents |
M. D. Goncharov, A. A. Savchenko, Yu. I. Grinshtein, I. I. Gvozdev, A. A. Kosinova, T. S. Mongush | ||
"... bypass grafting (CABG), depending on sensitivity to emacetylsalicylic/em acid (ASA). Material and methods ..." | ||
Vol 17, No 4 (2021) | Monitoring of Aspirin Therapy in Patients with Cerebrovascular Pathology | Abstract similar documents |
M. M. Tanashyan, A. A. Raskurazhev, A. A. Kornilova, A. A. Shabalina, D. A. Abaimov, A. V. Naminov | ||
"... manifestations of CVD. All patients received emacetylsalicylic/em acid (ASA) 75 mg daily. Along with a comprehensive ..." | ||
Vol 11, No 2 (2015) | CLINICAL CASE HISTORY OF EPTIFIBATIDE USE DURING CORONARY INTERVENTION IN PATIENT WITH CORONARY FAILURE | Abstract similar documents |
K. A. Kireev, A. V. Krasnopeev, T. S. Kireeva | ||
"... antiplatelet drugs (emacetylsalicylic/em acid and emclopidogrel/em) and heparin. There were not any reasons ..." | ||
Vol 16, No 3 (2020) | A Prospective, Initiative, Single-Center Open Post-Registration Comparative Study of Laboratory Efficacy of Various Forms of Acetylsalicylic Acid in a Cardioprotective Dose with Different Composition of Excipients: Results of the SFAIROS Study | Abstract similar documents |
N. V. Lomakin, L. I. Buryachkovskaya, D. A. Zolin, V. I. Kazey | ||
"... and pharmacokinetic parameters of branded generic preparations of emacetylsalicylic/em acid (ASA) in buffered form ..." | ||
Vol 14, No 2 (2018) | DOCTOR’S ADHERENCE TO RECOMMENDATIONS GOVERNING THE ANTIPLATELET AGENTS USE IN THE CARDIOVASCULAR DISEASES PREVENTION AND TREATMENT | Abstract similar documents |
N. В. Perepech, A. V. Tregubov | ||
"... . 51.8% of respondents recommend a combination of emacetylsalicylic/em acid and emclopidogrel/em ..." | ||
Vol 18, No 1 (2022) | The Impact of Combination Therapy with Rivaroxaban and Acetylsalicylic Acid in Patients with Coronary Heart Disease on the Achievement of the Target for Reducing Mortality from Cardiovascular Diseases of the Federal Project "Fight against Cardiovascular Diseases" | Abstract similar documents |
M. V. Zhuravleva, A. V. Panov, A. R. Kuksenok | ||
"... Aim. To assess the outcomes of combination therapy with rivaroxaban and emacetylsalicylic/em acid (ASA ..." | ||
Vol 15, No 2 (2019) | The Use of Dual Antiplatelet Therapy in Acute Coronary Syndrome and Percutaneous Coronary Intervention | Abstract similar documents |
A. S. Tereshchenko, E. V. Merkulov, A. N. Samko, S. A. Abugov | ||
"... and prevention of acute coronary syndrome. Double antiplatelet therapy is a combination of emacetylsalicylic/em acid ..." | ||
Vol 7, No 6 (2011) | PHARMACOTHERAPY ANALYSIS OF ACUTE ST-ELEVATION MYOCARDIAL INFARCTION IN HOSPITALS OF VARIOUS TYPES | Abstract similar documents |
R. M. Magdeev, O. V. Reshetko, E. Y. Rudnichenko, N. V. Furman, P. V. Dolotovskaya, T. Y. Grozdova, L. N. Volkova | ||
"... %, respectively). In MH dipyridamole was used in 9.6% of patients as an alternative to the emacetylsalicylic/em acid ..." | ||
Vol 7, No 6 (2011) | CORONARY EMBOLISM WITH FRAGMENTED THROMBUS FROM THE LEFT VENTRICLE IN PATIENT WITH POSTINFARCTION ANEURYSM | Abstract similar documents |
Yu. F. Salakhova, S. V. Gar'kina, T. V. Kislukhin, D. V. Duplyakov, V. S. Ivanov, E. R. Perunova, E. I. Bazhenova, S. E. Burnazyan, S. M. Khokhlunov | ||
"... therapy (emacetylsalicylic/em acid, emclopidogrel/em, warfarin) was made on the 4th day of disease onset taking ..." | ||
Vol 18, No 5 (2022) | The Problem of Drug Interactions Between Rosuvastatin and Ticagrelor in the Aspect of the Risk of Rhabdomyolysis: Discussion of the Problem and Description of the Clinical Case | Abstract similar documents |
O. V. Gaisenok, Yu. M. Chichkov, M. V. Leonova | ||
"... Background. Combination therapy with two antiplatelet agents (ticagrelor or emclopidogrel/em plus ..." | ||
Vol 14, No 2 (2018) | FIVE-YEAR DYNAMICS OF SECONDARY PREVENTION IN PATIENTS WITH STABLE ANGINA AT SPECIALIZED OUT-PATIENT LEVEL IN MOSCOW (PHARMACOEPIDEMIOLOGY STUDY) | Abstract similar documents |
S. В. Fitilev, I. I. Shkrebneva, A. V. Vozzhaev, K. O. Tsukanova | ||
"... of recommendations of emacetylsalicylic/em acid as monotherapy (down to 93.0%) and increased – in combination ..." | ||
Vol 11, No 4 (2015) | EVALUATION OF COST-EFFECTIVENESS OF PLATELET REACTIVITY ANALYSIS USING THE VERIFYNOW P2Y12 ASSAY IN PATIENTS AFTER ACUTE CORONARY SYNDROME | Abstract similar documents |
A. V. Rudakova, N. V. Lomakin | ||
"... Dual antiplatelet therapy, including emclopidogrel/em and aspirin, in a significant share of patients ..." | ||
Vol 6, No 5 (2010) | LONG-TERM THERAPY WITH ACETYLSALICYLIC ACID. HOW TO AVOID THE POSSIBLE COMPLICATIONS? | Abstract similar documents |
I. V. Zhirov | ||
"... Data about efficacy and safety of long-term therapy with emacetylsalicylic/em acid in patients ..." | ||
Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
"... ), encoding P-glycoprotein, in pharmacotherapy with digoxin, antiplatelet drugs (emclopidogrel/em tikagrelol ..." | ||
Vol 9, No 1 (2013) | OUTPATIENT REGISTER OF CARDIOVASCULAR DISEASES IN THE RYAZAN REGION (RECVASA): PRINCIPAL TASKS, EXPERIENCE OF DEVELOPMENT AND FIRST RESULTS | Abstract PDF (Eng) similar documents |
S. A. Boytsov, S. S. Yakushin, S. Yu. Martsevich, M. M. Lukyanov, N. N. Nikulina, A. V. Zagrebelny, A. N. Vorobyov, K. G. Pereverseva, E. A. Pravkina, A. D. Deev, E. Yu. Andreenko, A. I. Ershova, A. N. Meshkov, R. P. Myasnikov, S. E. Serdyuk, М. S. Kharlap | ||
"... : antiplatelet agents – in 60.4% of the cases (584 patients received emacetylsalicylic/em acid and 20 – emclopidogrel/em ..." | ||
Vol 7, No 4 (2011) | VASCULAR BED PECULIAR PROPERTIES IN PATIENTS WITH ISCHEMIC HEART DISEASE AND ARTERIAL HYPERTENSION. ROLE OF ANTIPLATELET THERAPY | Abstract similar documents |
L. A. Haisheva, S. V. Shlyk | ||
"... of revealed disorders with antiplatelet agent — emclopidogrel/em 75 mg/day. Material and methods. 40 patients ..." | ||
Vol 16, No 2 (2020) | LIS-3 Acute Coronary Syndrome Registry: Changes in Clinical and Demographic Characteristics and Tactics of Prehospital and Hospital Treatment of Surviving Patients After Acute Coronary Syndrome Over a 4-Year Period | Abstract similar documents |
S. Yu. Martsevich, A. V. Zagrebelnyy, N. P. Zolotareva, N. P. Kutishenko, Yu. V. Lukina, M. L. Ginzburg, D. A. Startsev, S. V. Blagodatskikh | ||
"... of use of emacetylsalicylic/em acid, emclopidogrel/em, statins, beta-blockers, ACE inhibitors, angiotensin II ..." | ||
Vol 17, No 1 (2021) | Multivariable Analysis of Primary Care Physician Adherence to Guideline-recommended Pharmacotherapy of Stable Coronary Artery Disease | Abstract similar documents |
S. K. Zyryanov, S. B. Fitilev, A. V. Vozzhaev, I. I. Shkrebniova | ||
"... contraindications) were quite adequate: beta-blockers/calcium channel blockers – 90,1%, emacetylsalicylic/em acid ..." | ||
Vol 7, No 2 (2011) | PECULIAR PROPERTIES OF ANTITHROMBOTIC THERAPY IN PATIENTS WITH ARTERIAL HYPERTENSION. IS IT POSSIBLE TO DO THE TREATMENT SAFE? | Abstract similar documents |
I. V. Zotova, D. A. Zateyshchikov | ||
Vol 18, No 1 (2022) | Cerebrovascular Accident in a Patient with Polycythemia: a Case Report | Abstract similar documents |
O. M. Drapkina, I. I. Almazova, A. V. Smirnova, S. A. Berns, R. N. Shepel | ||
Vol 20, No 2 (2024) | Characteristics of the Russian population of patients with coronary artery disease or peripheral artery disease in the XATOA registry | Abstract similar documents |
V. S. Arakelyan, A. D. Erlikh, N. Sh. Amirov, E. Dubar, K. Vogtlaender, S. Debus | ||
"... inhibition therapy with rivaroxaban 2,5 mg twice a day and low-dose emacetylsalicylic/em acid (ASA) daily were ..." | ||
Vol 7, No 5 (2011) | THE ADHERENCE TO RECOMMENDED THERAPY IN PATIENTS AFTER ACUTE CORONARY SYNDROME, AND RISK OF CARDIOVASCULAR COMPLICATIONS WITHIN A YEAR AFTER HOSPITAL ADMISSION | Abstract similar documents |
N. F. Puchin'yan, Ya. P. Dovgalevskiy, P. V. Dolotovskaya, N. V. Furman | ||
"... . Complex therapy (emacetylsalicylic/em acid (ASA), beta-blockers (BB), ACE inhibitors, statins) was prescribed ..." | ||
Vol 13, No 2 (2017) | RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY | Abstract similar documents |
. Editorial | ||
Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
A. V. Rudakova, V. A. Parfenov | ||
"... K antagonists (such as warfarin), antiplatelet therapy (such as emacetylsalicylic/em acid) and novel oral ..." | ||
Vol 14, No 3 (2018) | THE POSSIBILITIES OF USING A NEW FIXED-DOSE COMBINATION OF ROSUVASTATIN AND ACETYLSALICYLIC ACID: FOCUS GROUPS OF PATIENTS | Abstract similar documents |
O. D. Ostroumova, A. I. Kochetkov, N. Yu. Voevodina, S. S. Sharonova | ||
"... are presented. Current data on the pattern of antiplatelet use, including emacetylsalicylic/em acid, in individuals ..." | ||
Vol 14, No 2 (2018) | CHANGE IN THE FUNCTIONAL STATE OF ERYTHROCYTES AS A COMPONENT OF MICROCIRCULATORY DISORDERS IN METABOLIC SYNDROME | Abstract similar documents |
V. I. Podzolkov, T. V. Koroleva, A. Е. Bragina, M. G. Kudryavtseva, N. A. Druzhinina, M. V. Pisarev | ||
"... Aim. To study the emerythrocyte/em electric charge (EEC) in patients with metabolic syndrome (MS ..." | ||
Vol 14, No 3 (2018) | RELATION OF DISTURBANCES IN THE ERYTHROCYTES ELECTRICAL ACTIVITY WITH DYSLIPIDEMIA IN THE METABOLIC SYNDROME | Abstract similar documents |
V. I. Podzolkov, T. V. Koroleva, A. E. Bragina, M. G. Kudryavtseva, G. I. Bragina, M. V. Pisarev | ||
"... Aim. To study the emerythrocyte/em electric charge (EEC) in patients with metabolic syndrome (MS ..." | ||
Vol 15, No 3 (2019) | Effect of Hyperglycemia on the Total Surface Charge of the Erythrocyte Membrane in Patients with Metabolic Syndrome | Abstract similar documents |
V. I. Podzolkov, T. V. Koroleva, M. G. Kudryavtseva | ||
"... Aim. To study the effect of hyperglycemia on the total surface charge of the emerythrocyte/em membrane ..." | ||
Vol 6, No 2 (2010) | EFFICACY AND SAFETY OF ACIDUM ACETYLSALICYLICUM USAGE | Abstract similar documents |
V. N. Drozdov, V. A. Kim | ||
"... Data about efficacy and safety of emacetylsalicylic/em acid usage as antiplatelet drug and for cancer ..." | ||
Vol 15, No 3 (2019) | Treatment of Patients with Stable Manifestations of Atherosclerosis: New Opportunities | Abstract similar documents |
article Editorial | ||
"... and emacetylsalicylic/em acid can be recommended after registration of the indication for almost all patients ..." | ||
Vol 5, No 1 (2009) | CHANGES OF INTERCELLULAR COOPERATION IN PERIPHERAL BLOOD IN TREATED PATIENTS WITH CARDIOLOGIC DISEASES | Abstract similar documents |
L. N. Korichkina, V. S. Volkov | ||
"... , autorosettes and autorosettes with emerythrocyte/em lysis was calculated. The cellular association consisting ..." | ||
Vol 17, No 4 (2021) | Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention | Abstract similar documents |
A. V. Panov | ||
"... antithrombotic therapy, preference should be given to emclopidogrel/em compared to other, more powerful P2Y12 ..." | ||
Vol 14, No 6 (2018) | Availability and Affordability of Medicines for the Treatment of Cardiovascular Diseases in Pharmacies in Six Regions of the Russian Federation | Abstract PDF (Eng) similar documents |
A. E. Imaeva, Yu. A. Balanova, A. V. Kontsevaya, A. V. Kapustina, D. V. Duplyakov, O. H. Malysheva, I. V. Osipova, T. A. Petrichko, G. I. Kropanin, R. A. Kasimov, D. A. Leon, M. McKee | ||
"... pharmacies. Among antiplatelet agents, aspirin was available in most pharmacies, and emclopidogrel/em was mostly ..." | ||
Vol 14, No 6 (2018) | Antithrombotic Therapy in Patients with Atrial Fibrillation after Myocardial Infarction: Clinical Guidelines and Actual Practice | Abstract PDF (Eng) similar documents |
K. G. Pereverzeva, S. S. Yakushin, A. E. Pripadcheva, N. P. Agaltsova | ||
"... (3.8%) patients. Aspirin was the only antiplatelet agent in 3 cases and emclopidogrel/em – in one case ..." | ||
Vol 9, No 6 (2013) | THROMBOLYSIS OR PRIMARY PCI FOR MYOCARDIAL INFARCTION WITH ST-SEGMENT ELEVATION? THE STREAM TRIAL (STRATEGIC REPERFUSION EARLY AFTER MYOCARDIAL INFARCTION) | Abstract similar documents |
V. A. Sulimov | ||
"... by half in patients aged ≥75 years) in combination with emclopidogrel/em and enoxaparin followed by admission ..." | ||
Vol 14, No 1 (2018) | COMPARATIVE ANALYSIS OF HOSPITAL PHARMACOTHERAPY OF CHRONIC HEART FAILURE WITH REDUCED LEFT VENTRICULAR EJECTION FRACTIONS IN 2009-2010 AND 2014-2015 | Abstract similar documents |
O. V. Reshetko, A. V. Sokolov, E. V. Rykalina, N. V. Furman | ||
"... receptors (AMCR), diuretics, oral anticoagulants, emclopidogrel/em increased (p0.05). In the structure ..." | ||
Vol 12, No 5 (2016) | Clinical and Laboratory Predictors of Major Adverse Cardiac Events in Patients with Ischemic Heart Disease Following Elective Percutaneous Coronary Intervention | Abstract similar documents |
E. Z. Golukhova, M. V. Grigoryan, M. N. Ryabinina, N. I. Bulaeva | ||
"... antiplatelet therapy with acetyl salicylic acid and emclopidogrel/em. Numerous clinical characteristics ..." | ||
Vol 16, No 5 (2020) | Treatment of Patients with Acute Coronary Syndrome with ST Segment Elevation in Clinical Practice of the Republic of Karelia: the Results of 10-year Register | Abstract similar documents |
I. S. Skopets, N. N. Vezikova, A. V. Malafeev, A. N. Malygin, V. A. Litvinova | ||
"... .8% – emclopidogrel/em, 91.1% – anticoagulants, 91.6% – beta-blockers, 95.6% – statins, 94.2% – angiotensin-converting ..." | ||
Vol 8, No 4 (2012) | THE RISK OF BLEEDINGS IN PATIENTS WITH ATRIAL FIBRILLATION DURING ANTICOAGULANT THERAPY | Abstract similar documents |
M. Yu. Gilyarov | ||
"... . Along with traditional drugs (emacetylsalicylic/em acid, warfarin) rivaroxaban is specially considered ..." | ||
Vol 8, No 2 (2012): | РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ ОСТРОГО КОРОНАРНОГО СИНДРОМА БЕЗ СТОЙКОГО ПОДЪЕМА СЕГМЕНТА ST | Abstract similar documents |
, , , , , , , , , , , , , , , , | ||
Vol 13, No 4 (2017) | PROLONGED DUAL ANTIPLATELET THERAPY AFTER MYOCARDIAL INFARCTION: WHAT THE RESULTS OF THE PEGASUS-TIMI 54 TRIAL SHOW | Abstract similar documents |
I. S. Yavelov | ||
"... and safety of prolonged use of a combination of emacetylsalicylic/em acid and blocker P2Y12 platelet receptor ..." | ||
Vol 16, No 4 (2020) | Cardiovascular Comorbidity: Patient with Coronary Artery Disease and Peripheral Artery Atherosclerosis. How to Identify and Manage the Risks of Ischemic Events? | Abstract similar documents |
O. L. Barbarash, V. V. Kashtalap, I. A. Shibanova | ||
"... and the antiplatelet agent – emacetylsalicylic/em acid, are highlighted on the basis of the results of clinical studies ..." | ||
Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
A. V. Rudakova | ||
"... (warfarin), antiplatelet therapy (emacetylsalicylic/em acid) and novel oral anticoagulants such as apixaban ..." | ||
Vol 15, No 6 (2019) | New Opportunities for Improving the Prognosis of Patients with Chronic Ischemic Heart Disease | Abstract similar documents |
N. B. Perepech | ||
"... and emacetylsalicylic/em acid on the prognosis of patients with chronic IHD or peripheral artery disease, are presented ..." | ||
Vol 9, No 2 (2013) | TREATMENT OF PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE IN REAL CLINICAL PRACTICE ACCORDING TO THE DATA FROM PROGNOZ IBS REGISTER. (Part 1) | Abstract similar documents |
S. N. Tolpygina, Yu. N. Polyanskaya, S. Yu. Martsevich | ||
"... increased from 20% to 84.4%, statins - from 10% to 85.5%, β-blockers - from 20% to 91%, emacetylsalicylic/em acid ..." | ||
Vol 2, No 4 (2006) | THROMBOLYTIC THERAPY IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION | Abstract similar documents |
E. V. Konstantinova, A. V. Magnitskyi, N. A. Schostak | ||
"... and safety of fibrinolytics by their combination with emacetylsalicylic/em acid, IIb/IIIa receptor inhibitors ..." | ||
Vol 7, No 1 (2011) | DYSLIPIDEMIA FEATURES IN CHILDREN | Abstract similar documents |
T. I. Turkinа, M. Yu. Shcherbakova | ||
"... ) in children are discussed. Spectra lipids, phospholipids and lipoproteins in blood serum and emerythrocyte/em ..." | ||
Vol 4, No 4 (2008) | EFFICACY AND SAFETY OF GINKGO BILOBA IN ELDERLY PATIENTS WITH CONTROLLED ARTERIAL HYPERTENSION AND CIRCULATORY ENCEPHALOPATHY | Abstract similar documents |
V. V. Jakusevich, N. V. Semenova, I. A. Tihomirova, A. V. Muravyov, S. V. Lychenko | ||
"... were estimated during the study. The rheological indicators (blood, plasma and emerythrocyte/em suspension ..." | ||
1 - 100 of 126 Items | 1 2 > >> |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)